Nickname: Gaz

Review: Interested in the article mainly because of the similarity of the battle for supremacy between Roche and GSK over Relenza and Tamiflu (of the marketing campain mentioned between Merk and Amgen with Merk's product having side efects) Tamiflu has shown resistence to flu strains yet GSK have not promoted their superior drug Relenza.Is this because they are being sued by the inventor company for $430million for not marketing and exposing the drug and they are trying to take over biota or is it because Rumsfeld was a director of Gilead when Tamiflu was tested and it has been sponsered by USA government purchases on flawed scientific analisis. Either way there is alot of untold story in this Flu pandemic time of GSK/Roche,Relenza/Tamiflu,Gilead/Biota. Hope you can investigate and shed some light for investors!!!! Cheers Gaz

Date reviewed: Jan 29, 2006 1:18 AM

Nickname: Big Dog

Review: I look to see Amgen at $95 by years end. Amgen is a great buying opportunity at $71.

Date reviewed: Jan 27, 2006 2:35 PM